From Insulin to GLP-1s — a Peptide Saga: The Drugs That Shape Us, Episode 4

Chain Reaction by ACS

If you’re on social media, you may feel bombarded by influencers promoting peptides for a range of ailments so broad it almost seems like a brand-new trend. But peptide-based therapies actually date back to 1922, when insulin was first administered to treat diabetes. But it wasn’t until semaglutide (better known as Ozempic) entered the market that peptides truly captured public attention. In today’s episode, we explore how what chemists and other scientists learned from insulin paved the way for the remarkable effectiveness of GLP-1 drugs, and how treatments originally developed for diabetes are now being used to address obesity, substance use, and more.

Transcripts and episode sources at acs.org/chainreaction

More description

If you’re on social media, you may feel bombarded by influencers promoting peptides for a range of ailments so broad it almost seems like a brand-new trend. But peptide-based therapies actually date back to 1922, when insulin was first administered to treat diabetes. But it wasn’t until semaglutide (better known as Ozempic) entered the market that peptides truly captured public attention. In today’s episode, we explore how what chemists and other scientists learned from insulin paved the way for the remarkable effectiveness of GLP-1 drugs, and how treatments originally developed for diabetes are now being used to address obesity, substance use, and more.

Transcripts and episode sources at acs.org/chainreaction

2026-09-03 41 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.